Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to $439000.0.

  • Oncology Institute's Change in Account Payables fell 9420.69% to $439000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 3234.43%. This contributed to the annual value of $9.2 million for FY2024, which is 8222.27% up from last year.
  • Oncology Institute's Change in Account Payables amounted to $439000.0 in Q3 2025, which was down 9420.69% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Change in Account Payables ranged from a high of $7.6 million in Q3 2024 and a low of -$5.5 million during Q2 2024
  • Over the past 5 years, Oncology Institute's median Change in Account Payables value was $739000.0 (recorded in 2024), while the average stood at $1.2 million.
  • Its Change in Account Payables has fluctuated over the past 5 years, first crashed by 72510.55% in 2022, then surged by 350857.14% in 2024.
  • Over the past 5 years, Oncology Institute's Change in Account Payables (Quarter) stood at -$3.3 million in 2021, then surged by 46.52% to -$1.8 million in 2022, then soared by 161.47% to $1.1 million in 2023, then crashed by 32.57% to $739000.0 in 2024, then tumbled by 40.6% to $439000.0 in 2025.
  • Its Change in Account Payables stands at $439000.0 for Q3 2025, versus $6.4 million for Q2 2025 and $5.1 million for Q1 2025.